Price (delayed)
$6.9
Market cap
$396.61M
P/E Ratio
23.79
Dividend/share
N/A
EPS
$0.29
Enterprise value
$335.77M
kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology
There are no recent dividends present for KMDA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.